

References

1. von Brunn A. Beiträge zur mikroskopischen Anatomie der menschlichen Nasenhöhle. *Arch Mikr Anat* 1892; 39:632-651.
2. Read EA. A contribution to the knowledge of the olfactory apparatus in dog, cat and man. *Am J Anat* 1908; 8:17-47.
3. Féron F, Perry C, McGrath J, Mackay-Sim A. New techniques for biopsy and culture of human olfactory epithelia neurons. *Arch Otolaryngol Head Neck Surg* 1998; 124:861-866.
4. Say P, Leopold DA, Cochran G, Smith L, Greiner T. Resection of the inferior superior turbinate: Does it affect olfactory ability or contain olfactory neuronal tissue? *Am J Rhinol* 2004; 18:157-160.
5. Leopold DA, Hummel T, Schwob JE, Hong SC, Knecht M, Kobal G. Anterior distribution of human olfactory epithelium. *Laryngoscope* 2000; 110:417-421.
6. Doty RL, Mishra A. Olfaction and its alteration by nasal obstruction, rhinitis and rhinosinusitis. *Laryngoscope* 2001; 111:409-423.
7. Firestein S. How the olfactory system makes sense of scents. *Nature* 2001; 413:211-218.
8. Costanzo RM, Graziadei PPC. Development and plasticity of the olfactory system. In: Finger TE, Silver WL, editors. *Neurobiology of smell and taste*. New York: John Wiley & Sons, 1987: 233-250.
9. Conley DB, Robinson AM, Shinners MJ, Kern RC. Age-related olfactory dysfunction: cellular and molecular characterization in the rat. *Am J Rhinol* 2003; 17:169-175.
10. Murphy C, Schubert CR, Cruickshanks KJ, Klein BE, Klein R, Nondahl DM. Prevalence of olfactory impairment in older adults. *JAMA* 2002; 288:2307-2312.
11. Paik SI, Lehman MN, Seiden AM, Duncan HJ, Smith DV. Human olfactory biopsy: the influence of age and receptor distribution. *Arch Otolaryngol Head Neck Surg* 1992; 118:731-738.
12. Schwob JE. Neural regeneration and the peripheral olfactory system. *Anat Rec* 2002; 269:33-49.
13. Perry C, Mackay-Sim A, Féron F, McGrath J. Olfactory neural cells: an untapped diagnostic and therapeutic resource. *Laryngoscope* 2002; 112:603-607.
14. Santos-Benito FF, Ramón-Cueto A. Olfactory ensheathing glia transplantation: a therapy to promote repair in the mammalian central nervous system. *Anat Rec* 2003; 271B:77-85.
15. Zatorre RJ, Jones-Gotman M, Evans AC, Meyer E. Functional localization and lateralization of human olfactory cortex. *Nature* 1992; 360:339-340.
16. Yousem DM, Williams SCR, Howard RO et al. Functional MR imaging during Odor stimulation: preliminary data. *Radiology* 1997; 204:833-838.
17. Deems DA, Doty RL, Settle G et al. Smell and taste disorders, a study of 750 patients from the university of Pennsylvania smell and taste center. *Arch Otolaryngol Head Neck Surg* 1991; 117:519-528.
18. Miwa T, Furukawa M, Tsukatani T, Costanzo RM, DiNardo LJ, Reiter ER. Impact of olfactory impairment on quality of life and disability. *Arch Otolaryngol Head Neck Surg* 2001; 127:497-503.
19. Hedén Blomqvist E, Brämerson A, Stjärne P, Nordin S. Consequences of olfactory loss and adopted coping strategies. *Rhinology*. In press.
20. Temmel AFP, Quint C, Schickinger-Fischer B, Klimek L, Stoller E, Hummel T. Characteristics of olfactory disorders in relation to major causes of olfactory loss. *Arch Otolaryngol Head Neck Surg* 2002; 128:635-641.
21. Santos DV, Reiter ER, DiNardo LJ, Costanzo RM. Hazardous events associated with impaired olfactory function. *Arch Otolaryngol Head Neck Surg* 2004; 130:317-319.
22. Hummel T, Nesztler C, Kallert S, Kobal G, Bende M, Nordin S. Gustatory sensitivity in patients with anosmia. *Chem Senses* 2001; 26:1118.
23. Nordin S, Monsch AU, Murphy C. Unawareness of smell loss in normal aging and Alzheimer's disease: discrepancy between self-reported and diagnosed smell sensitivity. *J Gerontol B Psychol Sci Soc Sci* 1995; 50B:187-192.
24. Landis BN, Hummel T, Hugentobler M, Giger R, Lacroix JS. Ratings of overall olfactory function. *Chem Senses* 2003; 28:691-694.
25. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: A standardized microencapsulated test of olfactory function UPSIT. *Physiol Behav* 1984; 32:489-502.
26. Doty RL, Marcus A, Lee WW. Development of the 12-Item cross-cultural smell identification test CC-SIT. *Laryngoscope* 1996; 106:353-356.
27. Cain WS, Gent JF, Goodspeed RB, Leonard G. Evaluation of olfactory dysfunction in the connecticut chemosensory clinical research center. *Laryngoscope* 1988; 98:83-88.
28. Kobal G, Hummel T, Sekinger B, Barz S, Roscher S, Wolf SR. „Sniffin' Sticks“: Screening of olfactory performance. *Rhinology* 1996; 34:222-226.
29. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. „Sniffin' Sticks“: olfactory performance assessed by the combined testing of odor identification, odor discrimination, and olfactory thresholds. *Chemical Senses* 1997; 22:39-52.
30. Kobal G, Klimek L, Wolfensberger M et al. Multicenter investigation of 1036 subjects using a standardized method for the assessment of olfactory function combining tests of odor identification, odor discrimination, and olfactory thresholds. *Eur Arch Otorhinolaryngol* 2000; 257:205-211.

31. Mösges R, Bartsch M, Hetzenrecker A et al. Eine pragmatische Geruchsprüfung. *HNO* 1990; 38:459-461.
32. Simmen D, Briner HR, Hess K. Screening of olfaction with smell diskettes. *Laryngo-Rhino-Otol* 1999; 78:125-130.
33. Briner HR, Simmen D. Smell diskettes as screening test of olfaction. *Rhinology* 1999; 37:145-148.
34. Zusho H, Asaka H, Okamoto M. Diagnosis of olfactory disturbance. *Auris Nasus Larynx* 1981; 8:19-26.
35. Furukawa M, Kamide M, Miwa T, Umeda R. Significance of intravenous olfaction test using thiamine propylidisdulide Alinamin in olfactometry. *Auris Nasus Larynx* 1988; 15:25-31.
36. Kobal G, Plattig KH. Methodische Anmerkungen zur Gewinnung olfaktorischer EEG-Antworten des wachen Menschen objektive Olfaktometrie. *Z EEG-EMG* 1978; 9:135-145.
37. Welge-Lüsssen A, Wolfensberger M, Kobal G, Hummel T. Grundlagen, Methoden und Indikationen der objektiven Olfaktometrie. *Laryngo-Rhino-Otol* 2002; 81:661-667.
38. Riechstörungen - Leitlinie zur Epidemiologie, Pathophysiologie, Klassifikation, Diagnose und Therapie. http://www.uni-duesseldorf.de/AWMF/II/hno_II50.htm. 2004.
39. Förster G, Damm M, Gudziol H et al. Riechstörungen: Epidemiologie, pathophysiologische Klassifikation, Diagnose und Therapie. *HNO* 2004; 52:679-684.
40. Hoffmann HJ, Ishii EK, MacTurk RH. Age-related changes in the prevalence of smell/taste problems among the United States adult population: results of the 1994 disability supplement to the National Health Interview Survey NHIS. *Ann N Y Acad Sciences* 1998; 855:716-722.
41. Brämerson A, Johansson L, Ek L, Nordin S, Bende M. Prevalence of olfactory dysfunction: The Skövde population-based study. *Laryngoscope* 2004; 114:733-737.
42. Landis BN, Konnerth CG, Hummel T. A study on the frequency of olfactory dysfunction. *Laryngoscope* 2004; in press.
43. Damm M, Temmel A, Welge-Lüsssen A et al. Epidemiologie und Therapie von Riechstörungen in Deutschland, Österreich und der Schweiz. *HNO* 2004; 52:112-120.
44. Mott AE, Leopold DA. Disorders in taste and smell. *Med Clin N Am* 1991; 75:1321-1353.
45. Nordin S, Murphy C, Davidson TM, Quiñonez C, Jalowayski AA, Ellison DW. Prevalence and assessment of qualitative olfactory dysfunction in different age groups. *Laryngoscope* 1996; 106:739-742.
46. Quint C, Temmel AF, Schickinger B, Pabinger S, Ramberger P, Hummel T. Patterns of non-conductive olfactory disorders in eastern Austria: a study of 120 patients from the Department of Otorhinolaryngology at the University of Vienna. *Wien Klin Wochenschr* 2001; 113:52-57.
47. Cowart BJ, Flynn-Rodden K, McGeady SJ, Lowry LD. Hyposmia in allergic rhinitis. *J Allergy Clin Immunol* 1993; 91:747-751.
48. Simola M, Malmberg H. Sense of smell in allergic and nonallergic rhinitis. *Allergy* 1998; 53:190-194.
49. Apter AJ, Mott AE, Frank ME, Clive JM. Allergic rhinitis and olfactory loss. *Ann Allergy Asthma Immunol* 1995; 75:311-316.
50. Apter AJ, Gent JF, Frank ME. Fluctuating olfactory sensitivity and distorted odor perception in allergic rhinitis. *Arch Otolaryngol Head Neck Surg* 1999; 125:1005-1010.
51. Klimek L. Das Riechvermögen bei allergischer Rhinitis. *Pneumologie* 1998; 52:196-202.
52. Golding-Wood DG, Holmstrom M, Darby Y, Scadding GK, Lund VJ. The treatment of hyposmia with intranasal steroids. *J Laryngol Otol* 1996; 110:132-135.
53. Mott AE, Cain WS, Lafreniere D, Leonard G, Gent JF, Frank ME. Topical corticosteroid treatment of anosmia associated with nasal and sinus disease. *Arch Otolaryngol Head Neck Surg* 1997; 123:367-372.
54. Heilmann S, Huttenbrink KB, Hummel T. Local and systemic administration of corticosteroids in the treatment of olfactory loss. *Am J Rhinol* 2004; 18:29-33.
55. Tos M, Svendstrup F, Arndal H et al. Efficacy of an aqueous and a powder formulation of nasal budenoside compared in patients with nasal polyps. *Am J Rhinol* 1998; 12:183-189.
56. Lund VJ, Black JH, Szabó LZ, Schrewelius C, Akerlund A. Efficacy and tolerability of bedenoside aqueous nasal spray in chronic rhinosinusitis patients. *Rhinology* 2004; 42:57-62.
57. Lildholdt T, Rundcrantz H, Lindqvist N. Efficacy of topical corticosteroid powder for nasal polyps: a double-blind, placebo-controlled study of bedenoside. *Clin Otolaryngol* 1995; 20:26-30.
58. elNaggar M, Kale S, Aldren C, Martin F. Effect of beconase spray on olfactory function in post-nasal polypectomy patients: a prospective controlled trial. *J Laryngol Otol* 1995; 109:941-944.
59. Meltzer EO, Jalowayski AA, Orgel A, Harris AG. Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray. *J Allergy Clin Immunol* 1998; 102:39-49.
60. Stuck BA, Blum A, Hagner E, Hummel T, Klimek L, Hörmann K. Mometasone furoate nasal spray improves olfactory performance in seasonal allergic rhinitis. *Allergy* 2003; 58:1195-1216.
61. Hedén Blomqvist E, Lundblad L, Bergstedt H, Stjärne P. Placebo-controlled, randomized, double-blind study evaluating the efficacy of fluticasone propionate nasal spray for the treatment of patients with hyposmia/anosmia. *Acta Otolaryngol* 2003; 123:862-868.
62. Benninger MS, Hadley JA, Osguthorpe JD et al. Techniques of intranasal ster-

- oid use. *Otolaryngol Head Neck Surg* 2004; 130:5-24.
63. Hotchkiss WI. Influence of prednisone on nasal polyposis with anosmia. *Ann Allergy* 1956; 24:278-283.
64. Jafek BW, Moran DT, Eller PM. Steroid-dependent anosmia. *Arch Otolaryngol* 1987; 113:547-549.
65. Stevens MH. Steroid-dependent Anosmia. *Laryngoscope* 2001; 111:200-203.
66. Seiden AM, Duncan HJ. The diagnosis of a conductive olfactory loss. *Laryngoscope* 2001; 111:9-14.
67. Ikeda K, Sakurada T, Suzuki Y, Takasaka T. Efficacy of systemic corticosteroid treatment for anosmia with nasal and paranasal sinus disease. *Rhinology* 1995; 33:162-165.
68. Biacabe B, Faulcon P, Amanou L, Bonfils P. Olfactory cleft disease: An analysis of 13 cases. *Otolaryngol Head Neck Surg* 2004; 130:202-208.
69. Robinson AM, Kern RC, Foster JD, Fong KJ, Pitovski DZ. Expression of glucocorticoid receptor mRNA and protein in the olfactory mucosa; physiologic and pathophysiologic implications. *Laryngoscope* 1998; 108:1238-1242.
70. Robinson AM, Kern RC, Foster JD, Krozowski ZS, Pitovski DZ. Mineralocorticoid receptors in the mammalian olfactory tissue. *Ann Otol Rhinol Laryngol* 1999; 108:974-981.
71. Fong KJ, Kern RC, Foster JD, Zhao JC, Pitovski DZ. Olfactory secretion and sodium, potassium-adenosine triphosphatase: regulation by corticosteroids. *Laryngoscope* 1999; 109:383-388.
72. Bisgaard H. Pathophysiology of the cysteinyl leukotriens and effects of leukotriene receptor antagonist in asthma. *Allergy* 2001; 56:7-11.
73. Scadding GK. Comparison of medical and surgical treatment of nasal polyposis. *Curr Allergy Asthma Rep* 2002; 2:494-499.
74. Parnes SM, Chuma AV. Acute effects of antileukotriens on sinonasal polyposis and sinusitis. *Ear Nose Throat J* 2000; 79:18-25.
75. Cervin A. The anti-inflammatory effect of erythromycin and its derivates, with special reference to nasal polyposis and chronic sinusitis. *Acta Otolaryngol* 2001; 121:83-92.
76. Wolfensberger M, Hummel T. Anti-inflammatory and surgical therapy of olfactory disorders related to sino-nasal disease. *Chem Senses* 2002; 27:617-622.
77. Damm M, Vent J, Schmidt M. Intra-nasal volume and olfactory function. *Chem Senses* 2002; 27:831-839.
78. Jafek BW, Hill DP. Surgical Management of chemosensory disorders. *Ear Nose Throat J* 1989; 68:398-404.
79. Eichel BS. Improvement of olfaction following pansinus surgery. *Ear Nose Throat J* 1994; 73:248-253.
80. Delank KW, Stoll W. Die Riechfunktion vor und nach endonasaler Operation der chronisch polypösen Sinusitis. *HNO* 1994; 42:619-623.
81. Delank KW, Stoll W. Olfactory function after functional endoscopic sinus surgery for chronic sinusitis. *Rhinology* 1998; 36:15-19.
82. Downey LL, Jacobs JB, Lebowitz RA. Anosmia and chronic sinus disease. *Otolaryngol Head Neck Surg* 1996; 115:24-28.
83. Kimmelman CP. The risk to olfaction from nasal surgery. *Laryngoscope* 1994; 104:981-988.
84. Rowe-Jones JM, Mackay IS. A prospective study of olfaction following endoscopic sinus surgery with adjuvant medical treatment. *Clin Otolaryngol* 1997; 22:377-381.
85. Klimek L, Moll B, Amedee RG, Mann WJ. Olfactory function after microscopic endonasal surgery in patients with nasal polyps. *Am J Rhinol* 1997; 11:251-255.
86. Abdel-Hak B, Gunkel A, Kanonier G, Schrott-Fischer A, Ulmer H, Thumfart W. Ciliary beat frequency, olfaction and endoscopic sinus surgery. *ORL* 1998; 60:202-205.
87. Perry BP, Kountakis SE. Subjective improvement of olfactory function after endoscopic sinus surgery for chronic rhinosinusitis. *Am J Otolaryngol* 2003; 24:366-369.
88. Jankowski R, Pigret D, Decroocq F. Comparison of functional results after ethmoidectomy and nasalization for diffuse and severe nasal polyposis. *Acta Otolaryngol Stockh* 1997; 117:601-608.
89. Jankowski R, Bodino C. Olfaction in patients with nasal polyposis: effects of systemic steroids and radical ethmoidectomy with middle turbinate resection nasalisation. *Rhinology* 2003; 41:220-230.
90. Hedén Blomqvist E, Lundblad L, Änggård A, Haraldsson P-O, Stjärne P. A randomized controlled study evaluating medical treatment versus surgical treatment in addition to medical treatment of nasal polyposis. *J Allergy Clin Immunol* 2001; 107:224-228.
91. Elsberg CA, Levy I. The sense of smell: I. A new and simple method of quantitative olfactometry. *Bull Neurol Inst NY* 1935; 4:4-19.
92. Stevens CN, Stevens MH. Quantitative effects of nasal surgery on olfaction. *Am J Otolaryngol* 1985; 6:264-267.
93. Ophir D, Gross-Isseroff R, Lancet D, Marshak G. Changes in olfactory acuity induced by total inferior turbinectomy. *Arch Otolaryngol* 1986; 112:195-197.
94. Damm M, Eckel HE, Jungehülsing M, Hummel T. Olfactory changes at threshold and suprathreshold levels following septoplasty with partial inferior turbinectomy. *Ann Otol Rhinol Laryngol* 2003; 112:91-97.
95. Damm M, Eckel HE, Streppel M, Jungehülsing M, Stennert E. Abhängigkeit des uni-und bilateralen Riechvermögens von der nasalen Strömung bei Patienten mit chronischer Rhinosinusitis. *HNO* 2000; 48:436-443.

96. Jafek BW, Murrow B, Johnson EW. Olfaction and endoscopic sinus surgery. *Ear Nose Throat J* 1994; 73:548-552.
97. Seiden AM. Olfactory loss secondary to nasal and sinus pathology. In: Seiden AM, editor. *Taste and Smell Disorders*. New York: Thieme, 1997: 52-71.
98. Jafek BW, Murrow B, Michaels R, Restrepo D, Linschoten M. Biopsies of human olfactory epithelium. *Chem Senses* 2002; 27:623-628.
99. Lee SH, Lim HH, Lee HM, Park HJ, Choi JO. Olfactory mucosal findings in patients with persistent anosmia after endoscopic sinus surgery. *Ann Otol Rhinol Laryngol* 2000; 109:720-725.
100. Ge Y, Tsukatani T, Nishimura T, Furukawa M, Miwa T. Cell death of olfactory receptor neurons in a rat with nasosinusitis infected artificially with staphylococcus. *Chem Senses* 2002; 27:521-527.
101. Hengartner MO. The biochemistry of apoptosis. *Nature* 2000; 407:770-776.
102. Kern RC, Conley DB, Haines GK, Robinson AM. Pathology of the olfactory mucosa: implications for the treatment of olfactory dysfunction. *Laryngoscope* 2004; 114:279-285.
103. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. *Nature* 2000; 407:810-816.
104. Murphy C, Doty RL, Duncan HJ. Clinical disorders of olfaction. In: Doty RL, editor. *Handbook of Olfaction and Gustation*. New York, Basel: Marcel Dekker, 2003: 461-478.
105. Duncan HJ, Seiden AM. Long term-follow up of olfactory loss secondary to head trauma and upper respiratory tract infection. *Arch Otolaryngol Head Neck Surg* 1995; 123:367-372.
106. Hummel T. Therapie von Riechstörungen. *Laryngo-Rhino-Otol* 2003; 82:552-554.
107. Akerlund A, Bende M, Murphy C. Olfactory threshold and nasal mucosal changes in experimentally induced common cold. *Acta Otolaryngol* 1995; 115:88-92.
108. Hummel T, Rothbauer C, Barz S, Grosser K, Pauli E, Kobal G. Olfactory function in acute rhinitis. *Ann N Y Acad Sci* 1998; 855:616-624.
109. Hummel T, Rothbauer C, Pauli E, Kobal G. Effects of the nasal decongestant oxymetazoline on human olfactory and intranasal trigeminal function in acute rhinitis. *Eur J Clin Pharmacol* 1998; 54:521-528.
110. Jafek BW, Hartman D, Eller PM, Johnson EW, Strahan RC, Moran DT. Post-viral olfactory dysfunction. *Am J Rhinol* 1990; 4:91-100.
111. Yamagishi M, Fujiwara M, Nakamura H. Olfactory mucosal findings and clinical course in patients with olfactory disorders following upper respiratory viral infection. *Rhinology* 1994; 32:113-118.
112. Mori I, Goshima F, Imai Y et al. Olfactory receptor neurons prevent dissemination of neurovirulent influenza A virus into the brain by undergoing virus-induced apoptosis. *J Gen Virol* 2002; 83:2109-2116.
113. Mori I, Nishiyama Y, Yokochi T, Kimura Y. Virus-induced neuronal apoptosis as pathological and protective responses of the host. *Rev Med Virol* 2004; 14:209-216.
114. Hummel T, Heilmann S, Hüttenbrink K-B. Lipoid acid in the treatment of smell dysfunction following viral infection of the upper respiratory tract. *Laryngoscope* 2002; 112:2076-2080.
115. Leopold DA. Distortion of olfactory perception: Diagnosis and treatment. *Chem Senses* 2002; 27:611-615.
116. Leopold DA, Schwob JE, Youngentob SL, Hornung DE, Wright H, Mozell MM. Successfull treatment of phantosmia with preservataion of olfaction. *Arch Otolaryngol Head Neck Surg* 1991; 117:1402-1406.
117. Leopold DA, Loehrl TA, Schwob JE. Long-term follow-up of surgically treated phantosmia. *Arch Otolaryngol Head Neck Surg* 2002; 128:642-647.
118. Kern RC, Quinn B, Rousseau G, Farbman AI. Post-traumatic olfactory dysfunction. *Laryngoscope* 2000; 110:2106-2109.
119. Heywood PG, Zasler ND, Costanzo RM. Olfactory screening test for assessment of smell loss following traumatic brain injury. Proceedings of the 14th Annual Conference on Rehabilitation of the Brain Injured 1990; Williamsburg, Virginia.
120. Farbman AI. *Cell Biology of Olfaction*. New York: Cambridge Press, 1992.
121. Doty RL, Yousem DM, Pham LT, Kreshak AA, Geckle RJ, Lee WW. Olfactory dysfunction in patients with head trauma. *Arch Neurol* 1997; 54:1131-1140.
122. Yousem DM, Geckle RJ, Bilker WB, McKeown DA, Doty RL. Posttraumatic olfactory dysfunction: MR and clinical evaluation. *AJNR Am J Neuroradiol* 1996; 17:1171-1179.
123. Yousem DM, Geckle RJ, Bilker WB, Kroger H, Doty RL. Posttraumatic smell loss: relationship of psychophysical tests and volumes of the olfactory bulbs and tracts and the temporal lobes. *Acad Radiol* 1999; 6:264-272.
124. Costanzo RM, DiNardo LJ, Reiter ER. Head Injury and Olfaction. In: Doty RL, editor. *Handbook of Olfaction and Gustation*. New York, Basel: Marcel Dekker, 2003: 629-638.
125. Schwob JE, Szumowski KE, Stasky AA. Olfactory sensory neurons are trophically dependent on the olfactory bulb for their prolonged survival. *J Neurosci* 1992; 12:3896-3919.
126. Carr VM, Farbman AI. The dynamics of cell death in the olfactory epithelium. *Exp Neurol* 1993; 124:308-314.
127. Costanzo RM. Neural regeneration and functional reconnection following olfactory nerve transection in hamster. *Brain Res* 1985; 361:258-266.
128. Yee KK, Costanzo RM. Restoration of olfactory mediated behavior after olfactory bulb deafferentation. *Physiol Behav* 1995; 58:959-968.
129. Yee KK, Rawson NE. Retinoid acid enhances the rate of olfactory recovery

- after olfactory nerve transsection. *Develop Brain Res* 2000; 124:129-132.
130. Moran DT, Jafek BW, Rowley JC, Eller PM. Electron microscopy of olfactory epithelia in two patients with anosmia. *Arch Otolaryngol* 1985; 111:122-126.
131. Jafek BW, Eller PM, Esses BA, Moran DT. Post-traumatic anosmia. *Arch Neurol* 1989; 46:300-304.
132. Jafek BW, Johnson EW, Eller PM, Murrow B. Olfactory mucosal biopsy and related histology. In: Seiden AM, editor. *Taste and Smell disorders*. New York: Thieme, 1997: 107-127.
133. Aiba T, Sugiura M, Mori J et al. Effect of zinc sulfate on sensorineural olfactory disorder. *Acta Otolaryngol Stockh* 1998; Suppl 538:202-204.
134. Quint C, Temmel AFP, Hummel T, Ehrenberger K. The quinoxaline derivative caroverine in the treatment of sensorineural smell disorders: a proof-of-concept study. *Acta Otolaryngol* 2002; 122:877-881.
135. Ehrenberger K, Felix D. Caroverine depresses the activity of cochlear glutamate receptors in guinea pigs: in vivo model for drug-induced neuroprotection. *Neuropharmacology* 1992; 31:1259-1263.
136. Fujii M, Fukazawa K, Takayasu S, Sakagami M. Olfactory dysfunction in patients with head trauma. *Auris Nasus Larynx* 2002; 29:35-40.
137. Kallmann FJ, Schoenfeld WA, Barrera SE. The genetic aspects of primary eunuchoidisms. *Am J Mental Defic* 1944; 48:203-221.
138. Assouline S, Shevell MI, Zatorre RJ, Jones-Gotman M, Schloss M, Oudjhane K. Children who can't smell the coffee: isolated congenital anosmia. *J Child Neurol* 1998; 13:168-172.
139. Yousem DM, Geckle RJ, Bilker WB, McKeown DA, Doty RL. MR Evaluation of patients with congenital hyposmia or anosmia. *AJR* 1995; 166:439-443.
140. Abolmaali ND, Hietschold V, Vogl TJ, Huttenbrink KB, Hummel T. MR evaluation in patients with isolated anosmia since birth or early childhood. *Am J Neuroradiol* 2002; 23:157-164.
141. Jafek BW, Gordon AS, Moran DT, Eller PM. Congenital Anosmia. *Ear Nose Throat J* 1990; 69:331-337.
142. Leopold DA, Hornung DE, Schwob JE. Congenital lack of olfactory ability. *Ann Otol Rhinol Laryngol* 1992; 101:229-236.
143. Rawson NE, Brand JG, Cowart BJ et al. Functionally mature olfactory neurons from two anosmic patients with Kallmann syndrome. *Brain Res* 1995; 29:58-64.
144. Amoore JE. Effects of chemical exposure on olfaction in humans. In: Barlow CS, editor. *Toxicology of the Nasal Passages*. Washington, DC: Hemisphere Publishing, 1986: 155-190.
145. Doty RL, Hastings L. Neurotoxic exposure and olfactory impairment. *Clinic Occupat Environ Med Neurotoxicology* 2001; 1:547-575.
146. Hastings L, Miller MM. Influence on environmental toxicants on olfactory function. In: Doty RL, editor. *Handbook of Olfaction and Gustation*. New York, Basel: Marcel Dekker, 2003: 575-591.
147. deVries H, Stuiver M. The absolute sensitivity of the human sense of smell. In: Rosenblith WA, editor. *Sensory Communication*. New York: Wiley and Sons, 1961: 159-167.
148. Klimek L, Muttray A, Moll B, Konietzko J, Mann W. Riechstörungen durch inhalative Schadstoffexposition. *Laryngo-Rhino-Otol* 1999; 78:620-626.
149. Frasnelli J, Temmel AFP, Quint C, Oberbauer R, Hummel T. Olfactory function in chronic renal failure. *Am J Rhinol* 2002; 16:275-279.
150. Henkin RI. Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction. *Drug Saf* 1994; 11:318-377.
151. Ackerman BH, Kasbekar N. Disturbances of taste and smell induced by drugs. *Pharmacotherapy* 1997; 17:482-496.
152. Henkin RI, Larson AL. On mechanisms of hyposmia following laryngectomy in man. *Laryngoscope* 1972; 82:836-843.
153. Welge-Lüsssen A, Kobal G, Wolfensberger M. Assessing olfactory function in laryngectomees using the sniffin' sticks test battery and chemosensory evoked potentials. *Laryngoscope* 2000; 110:303-307.
154. Fujii M, Fukazawa K, Hatta C, Yasuno H, Sakagami M. Olfactory acuity after total laryngectomy. *Chem Senses* 2002; 27:117-121.
155. Gudziol H, Beleites E. Riechvermögen nach Laryngektomie. *Wiss Z Humboldt* 1991; 40:43-44.
156. Hilgers FJM, van Dam FSAM, Keyzers S, Koster MN, van As CJ, Muller MJ. Rehabilitation of olfaction after laryngectomy by means of a nasal airflow-inducing maneuver. *Arch Otolaryngol Head Neck Surg* 2000; 126:726-732.
157. Kopala LC, Good K, Honer WG. Olfactory identification ability in pre- and post-menopausal women with schizophrenia. *Biol Psychiatry* 1995; 38:57-63.
158. Dhong H-J, Chung S-K, Doty RL. Estrogen protects against 3-methylindole-induced olfactory loss. *Brain Res* 1999; 824:312-315.
159. Hughes LF, McAsey ME, Donathan CL, Smith T, Coney P, Struble RG. Effects of hormone replacement therapy on olfactory sensitivity: cross-sectional and longitudinal studies. *Climacteric* 2002; 5:140-150.
160. Féron F, Vincent A, Mackay-Sim A. Dopamine promotes differentiation of olfactory neuron in vitro. *Brain Res* 1999; 845:252-259.
161. Féron F, Perry C, Hirning MH, McGrath J, Mackay-Sim A. Altered adhesion, proliferation and death in neural cultures from adults with schizophrenia. *Schizophrenia Research* 1999; 40:211-218.
162. Huisman E, Uylings HBM, Hoogland PV. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's Disease. *Movement Disorders* 2004; 19:687-692.

163. Tanaka O, Mukaino Y. The effect of auricular acupuncture on olfactory acuity. *Am J Chin Med* 1999; 27:19-24.
164. Michael W. Anosmia treated with acupuncture. *Acupuncture in Medicine* 2003; 21:153-154.
165. Levy L, Henkin RI, Lin CS, Hutter A, Schellinger D. Increased brain activation in response to odors in patients with hyposmia after theophylline treatment demonstrated by fMRI. *J Comp Ass Tomography* 1998; 22:760-770.
166. Carr VM, Farbman AI. Ablation of the olfactory bulb up-regulates the rate of neurogenesis and induces precocious cell death in olfactory epithelium. *Exp Neurol* 1992; 115:55-59.
167. Farbman AI, Brunjes PC, Rentfro L, Michas J, Ritz S. The effect of unilateral naris occlusion on cell dynamics in the developing rat olfactory epithelium. *J Neurosci* 1988; 8:3290-3295.
168. Farbman AI, Ezeh PI. TGF-alpha and olfactory marker protein enhance mitosis in rat olfactory epithelium in vivo. *NeuroReport* 2000; 11:3655-3658.
169. Henkin RI, Lester L. Relationship between vitamin A metabolism and decreased olfactory detection sensitivity in patients with abetalipoproteinemia and other types of malabsorption. *J Clin Invest* 1967; 46:1069.
170. Garrett-Laster M, Russell RM, Jacques PF. Impairment of taste and olfaction in patients with cirrhosis: the role of vitamin A. *Hum Nutr Clin Nutr* 1984; 38C:203-214.
171. Henkin RI, Schechter PJ, Friedewald WT, Demets DL, Raff M. A double blind study of the effects of zinc sulfate on taste and smell dysfunction. *Am J Med Sci* 1976; 272:285-299.
172. Jafek BW, Linschoten M, Murrow B. Anosmia after intranasal zinc gluconate use. *Am J Rhinol* 2004; 18:137-141.
173. Miller IJJ, Bartoshuk LM. Taste perception, taste bud distribution, and spatial relationships. In: Getchell ML, Bartoshuk LM, Doty RL, Snow JBJ, editors. *Smell and Taste in Health and Disease*. New York: Raven Press, 1991: 205-233.
174. Beidler LM, Smallman RL. Renewal of cells within taste buds. *J Cell Biol* 1965; 27:263-272.
175. Miller IJJ, Reedy FEJ. Variations in human taste bud density and taste intensity perception. *Physiol Behav* 1990; 47:1213-1219.
176. Cullen MM, Leopold DA. Disorders of smell and taste. *Med Clin N Am* 2004; 83:57-74.
177. Smith DV. Basic anatomy and physiology of taste. In: Seiden AM, editor. *Taste and Smell Disorders*. New York: Thieme, 1997: 128-145.
178. Kinnamon SC. Taste transduction: a diversity of mechanisms. *Trends Neurosci* 1988; 11:491-496.
179. Kinnamon SC, Margolskee RF. Mechanisms of taste transduction. *Curr Opin Neurobiol* 1996; 6:506-513.
180. Welge-Lüsssen A, Gudziol H. Schmeckstörungen - Ursachen, Diagnostik und Therapie. *Therapeutische Umschau* 2004; 5:302-307.
181. Ahne G, Erras A, Hummel T, Kobal G. Assessment of gustatory function by means of tasting tablets. *Laryngoscope* 2000; 110B:1396-1401.
182. Henkin RI, Gill JRJ, Bartter FC. Studies on taste thresholds in normal man and in patients with adrenal cortical insufficiency: the role of adrenal cortical steroids and serum sodium concentration. *J Clin Invest* 1963; 42:727-735.
183. Hummel T, Knecht M. Smell and Taste disorders. In: Calhoun KH, editor. *Expert Guide to Otolaryngology*. Philadelphia, PA: American College of Physicians, 2001: 650-664.
184. Mueller C, Kallert S, Renner B et al. Quantitative assessment of gustatory function in a clinical context using impregnated „taste-strips“. *Rhinology* 2003; 41:2-6.
185. Haberland EJ, Fikentscher R, Roseburg B. Ein neues Elektrogustometer. *Msch Ohrenheilk* 1974; 108:254-258.
186. Schmeckstörungen - Leitlinie zur Epidemiologie, Pathophysiologie, Klassifikation, Diagnose und Therapie. http://www.uni-duesseldorf.de/AWMF/II/hno_II46.htm . 2004.
187. Bromley SM, Doty RL. Clinical Disorders affecting taste: evaluation and management. In: Doty RL, editor. *Handbook of Olfaction and Gustation*. New York: Marcel Dekker, 2003: 935-957.
188. Conger AD. Loss and recovery of taste acuity in patients irradiated to the oral cavity. *Radiat Res* 1973; 53:338-347.
189. Maes A, Huygh I, Weltens C et al. De Gustibus: time scale of loss and recovery of tastes caused by radiotherapy. *Radiother Oncol* 2002; 63:195-201.
190. Ripamonti C, Zecca E, Brunelli C et al. A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. *Cancer* 1998; 82:1938-1945.
191. Yamagata T, Nakamura H, Yamagata Y et al. The pilot trial of the prevention of the increase in electrical taste thresholds by zinc containing fluid infusion during chemotherapy to treat primary lung cancer. *J Exp Clin Cancer Res* 2003; 22:557-563.
192. Büntzel J, Schuth J, Küttner K, Glatzel M. Radiochemotherapy with amifostine cytoprotection for head and neck cancer. *Support Care Cancer* 1998; 6:155-160.
193. Tomita H, Ohtuka K. Taste disturbance after tonsillectomy. *Acta Otolaryngol* 2002; S 546:164-172.
194. Just T, Homoth J, Graumüller S, Pau HW. Schmeckstörung und Erholung der Schmeckfunktion nach Mittelohroperation. *Laryngo-Rhino-Otol* 2002; 82:494-500.
195. Saito T, Manabe Y, Shibamori Y et al. Long-Term follow-up results of electro-gustometry and subjective taste disorder after middle ear surgery. *Laryngoscope* 2001; 111:2064-2070.
196. Lehman CD, Bartoshuk LM, Catalanotto FC, Kveton JF, Lowlight RA. Effect of anesthesia of the chorda tympani

- nerve on taste perception in humans. *Physiol Behav* 1995; 57:943-951.
197. Robinson PP, Loescher AR, Smith KG. A prospective, quantitative study on the clinical outcome of lingual nerve repair. *Br J Oral Maxillofac Surg* 2002; 38:255-263.
198. Schiffman SS. Taste and smell losses in normal aging and disease. *JAMA* 1997; 278:1357-1362.
199. Mattes RD. The chemical senses and nutrition in aging: challenging old assumptions. *J Am Diet Assoc* 2002; 102:192-196.
200. Stoll AL, Oepen G. Zinc Salts for the treatment of olfactory and gustatory symptoms in psychiatric patients: a case series. *J Clin Psychiatry* 1994; 55:309-311.
201. Kitagoh H, Tomita H, Ikui A, Ikeda M. Course of recovery from taste receptor disturbance. *Acta Otolaryngol* 2002; S 546:83-93.
202. Sakai F, Yoshida S, Endo S, Tomita H. Double-blind,placebo-controlled trial of zinc picolinate for taste disorders. *Acta Otolaryngol* 2002; S 545:129-133.
203. Yoshida S, Endo S, Tomita H. A double-blind study of therapeutic efficacy of zinc gluconate on taste disorders. *Auris Nasus Larynx* 1991; 18:153-161.
204. Mahajan SK, Prasad AS, Lambujon J, Abbasi AA, Briggs WA, McDonald FD. Improvement of uremic hypogeusia by zinc: a double-blind study. *Am J Clin Nutr* 1980; 33:1517-1521.
205. Heckmann SM, Habiger S, Wichmann MG, Hummel T. Zinc gluconat in the treatment of dysgeusia: a double blinded controlled study. *Chem.Senses* 28, E24. 2003.
206. Heckmann JG, Heckmann SM, Lang CJ, Hummel T. Neurological aspects of taste disorders. *Arch Neurol* 2003; 60:667-671.
207. Deems DA, Yen DM, Kreshak AA, Doty RL. Spontaneous resolution of dysgeusia. *Arch Otolaryngol Head Neck Surg* 1996; 122:961-963.
208. Femiano F, Scully C. Burning mouth syndrome BMS: double blind controlled study of alpha-lipoic acid thiocctic acid therapy. *J Oral Pathol Med* 2002; 31:267-269.
209. Bull TR. Taste and the chorda tympani. *J Laryngol Otol* 1965; 79:479-493.
210. Bradley RM, Beidler LM. Saliva: Its role in taste function. In: Doty RL, editor. *Handbook of Olfaction and Gustation*. New York, Basel: Marcel Dekker, 2003: 639-650.
211. Bläker M, Kock K, Ahlers C, Buck F, Schmale H. Molecular cloning of human von Ebner's gland protein, a member of the lipocalin superfamily highly expressed in lingual salivary glands. *Biochem Biophys Acta Gene Struct Expression* 1993; 1172:131-137.
212. Van't Hof W, Blankenvoorde MFJ, Veerman ECI, Nieuw Amerongen AV. The salivary lipocalin von Ebner's gland protein is a cysteine proteinase inhibitor. *J Biol Chem* 1997; 272:1837-1841.
213. Henkin RI, Lippoldt R, Bilstad J, Edelhoch H. A zinc protein isolated from human parotid saliva. *Proc Natl Acad Sci USA* 1975; 72:488-492.
214. Thatcher BJ, Doherty AE, Orvisky E, Martin BM, Henkin RI. Gustin from human parotid saliva is carbonic anhydrase VI. *Biochem Biophys Res Commun* 1998; 250:635-641.
215. Henkin RI, Martin BM, Agarwal RP. Efficacy of exogenous oral zinc in treatment of patients with carbonic anhydrase VI deficiency. *Am J Med Sci* 1999; 318:392-404.
216. Henkin RI, Talal N, Larson AL, Mattern CFT. Abnormalities of taste and smell in Sjögren's syndrome. *Ann Intern Med* 1972; 76:375-383.
217. Weiffenbach JM, Fox PC, Baum BJ. Taste and salivary function. *Proc Natl Acad Sci USA* 1986; 83:6103-6106.
218. Catalanotto FA, Sweeney EA. Oral Conditions affecting chemosensory function. In: Getchell ML, Doty RL, Bartoshuk LM, Snow JBJ, editors. *Smell and Taste in Health and Disease*. New York: Raven Press, 1991: 643-651.
219. Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2004; 97:28-46.
220. Fox PC. Salivary enhancement therapies. *Caries Res* 2004; 38:241-246.
221. Ferraccioli GF, Salaffi F, De Vita S et al. Interferon alpha-2 IFN alpha 2 increases lacrimal and salivary function in Sjögren's syndrome patients: preliminary results of an open pilot trial versus OH-chloroquine. *Clin Exp Rheumatol* 1996; 14:367-371.
222. Ship JA, Fox PC, Michalek JE, Cummins MJ, Richards AB. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. *J Interferon Cytokine Res* 1999; 19:943-951.